Patent US3019683A successfully refreshed from Google Patents.
Patent US4833152A successfully refreshed from Google Patents.
US4833152A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Anti-hypertensive agents
Assignee: University of Miami
•
Filing: 1987-11-20
•
Granted: 1989-05-23
•
Expires: 2007-11-20
Abstract
Abstract Novel inhibitors of angiotensin coverting enzyme having the general formula R - A - S - Z are disclosed as potent inhibitors of angiotensin converting enzyme and are useful anti-hypertensive agents.
Inventors
- 👤 James W. Ryan
- 👤 Alfred Chung
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 19:33
CPC Classifications
C; C07; C07D; C07D403/00; C07D403/02; C07D403/12; C07C; C07C327/00; C07D207/00; C07D207/02; C07D207/04; C07D207/10; C07D207/16; C07D207/18; C07D207/22; C07D207/46; C07D207/50; C07D211/00; C07D211/04; C07D211/06; C07D211/36; C07D211/60; C07D211/62; C07D211/68; C07D211/72; C07D211/74; C07D211/76; C07D211/80; C07D211/84; C07D211/86; C07D277/00; C07D277/02; C07D277/04; C07D277/06; C07D417/00; C07D417/02; C07D417/12; C07K; C07K5/00; C07K5/04; C07K5/06; C07K5/06008; C07K5/06017; C07K5/06034; C07K5/06052; C07K5/0606; C07K5/06086; C07K5/06139; C07K5/06173; C07K5/08; C07K5/0821; A; A61; A61K; A61K38/00
Claims Analysis
Total Claims: 54
Claim 1
Independent Claim
811 words
A new compound having the general formula R-A-S-Z wherein R is hydrogen, formyl, acetyl, propanoyl, butanoyl, phenylacetyl, phenylpropanoyl, benzoyl, cyclopentanecarbonyl, tert-butyloxycarbonyl, cyclopentanecarbonyl-L-lysyl, pyro-L-glutamyl-L-lysyl, L-arginyl, L-lysyl or pyro-L-glutamyl; A is selected from proline, 3, 4-dehydroproline, -methyl proline, thiazolidine-4-carboxylic acid, cycloleucine, pyroglutamic acid, 1-amino-1-cyclopropane carboxylic acid, 1-amino-1-cyclobutane carboxylic acid, 1-amino-1-cyclohexane carboxylic acid and monosubstituted prolines wherein the substituent is halo or hydroxy, and is linked to R through its amino group or imino group and further is linked to S through its carboxyl group; S is a sulfur atom in thioester linkage with A; Z is selected from the following: ##STR69## wherein (i) R 1 and R 2 ', are each hydrogen or halogen, and R 2 and R 3 are each hydrogen, lower alkyl or trifluoromethyl provided that only one of R 2 and R 3 may be trifluoromethyl and further provided that at least one of R 1 , R 1 ', R 2 and R 3 must be halogen or trifluoromethyl (ii) R 23 is hydrogen or lower alkyl and (iii) m is 0 or 1; ##STR70## wherein (i) R 4 and R 5 are each hydrogen, lower alkyl or phenyllower alkylene (ii) N is 1, 2 or 3 (iii) R 6 is hydrogen or hydroxy or when n is 2, R 6 may also be halogen and (iv) m and R 23 are as stated in II. above; ##STR71## wherein (i) R 7 is hydrogen, lower alkanoyl or amino (imino)-methyl; (ii) p is 0 or an integer of from 1 to 4; (iii) R 25 is hydrogen but when m is 1, p is 0, R 4 is hydrogen and R 7 is lower alkanoyl, R 25 may also be lower alkyl; (iv) R 8 is selected from hydrogen, lower alkyl and hydroxy lower alkylene. When R 9 is selected from hydrogen, lower alkyl, phenyl, phenyl-lower alkylene, hydroxy-lower alkylene, hydroxyphenyl-lower alkylene, mercapto-lower alkylene, lower alkylthio-lower alkylene, imidazolyl-lower alkylene, indolyl-lower alkylene, carbamoyl-lower alkylene and carboxy-lower alkylene but R 8 and R 9 may together constitute a (CH 2 )ν bridge wherein ν is 3 or 4, thus forming a 5 or 6-membered ring with the N and C to which R 8 and R 9 are respectively attached and in such instance when ν is 3 one hydrogen of (CH 2 )ν may be replaced by OH or halogen and when ν is 4, one such hydrogen may be replaced by OH; (v) m and R 23 are each as defined in II. above; and (iv) R 4 is as defined in III. above, provided further, however, that m and p may not both be 0. ##STR72## wherein (i) R 10 is hydrogen or lower alkyl; (ii) R 11 is hydrogen, lower alkyl or lower alkanoyl; (iii) X is O or S; (iv) m and R 23 are as stated in II. above, and (v) R 8 , R 9 and p are as stated in IV. above; ##STR73## wherein (i) R 12 is selected from carboxy, lower alkoxycarbonyl, carbamoyl, N-substituted from carboyl and cyano; (ii) m and R 23 are as stated in II. above; and (iii) R 8 , R 9 and p are as stated in IV. above; ##STR74## wherein (i) R 13 is hydrogen, lower alkyl or phenyl-lower alkylene; (ii) R 14 is selected from hydrogen, lower alkyl, phenyl-lower alkylene, hydroxy-lower alkylene, amino lower alkylene, guanidino-lower alkylene, imidazolyl-lower alkylene, indolyl-lower alkylene, mercapto-lower alkylene, lower alkyl-thio-lower alkylene, carbamoyl-lower alkylene and carboxy-lower alkylene; (iii) R 4 and R 5 are each as stated in III, above; and (iv) q is 0, 1 or 2; ##STR75## wherein (i) R 15 and R 16 are each hydrogen, lower alkyl, phenyl or phenyl-lower alkylene; (ii) R is 0, 1 or 2; (iii) S is 1, 2 or 3; (iv) R 17 is hydrogen, hydroxy or lower alkyl and when S is R 17 may also be halogen; (v) R 24 is hydroxy, amino or lower alkoxy; ##STR76## wherein ii) R 18 is hydrogen or lower alkyl; (ii) R 19 and R 20 are each lower alkyl and may together constitute a (CH 2 ).sub.ω bridge wherein ω is 4, to form a ring of 5-carbons with the carbon to which they are each attached; (iii) R 21 is hydrogen or lower alkyl and may constitute with R 9 a (CH 2 )α bridge wherein α is 3, to form a five-membered ring with the N and C to which they are respectively attached; ##STR77## wherein (i) R 22 is hydrogen or lower alkyl; (ii) t is 0 or 1; and (iii) R 26 is selected from ##STR78## wherein μ is 0 or 1 and R 23 is as defined for formula II above, and ##STR79## wherein (i) z is 2 or 3; (ii) R 10 is as stated in V. above; and (iii) R 23 is as stated in II. above.
Claim 2
Dependent Claim
811 words
A new compound having the general formula R-A-S-Z wherein R is hydrogen, formyl, acetyl, propanoyl, butanoyl, phenylacetyl, phenylpropanoyl, benzoyl, cyclopentanecarbonyl, tert-butyloxycarbonyl, cyclopentanecarbonyl-L-lysyl, pyro-L-glutamyl-L-lysyl, L-arginyl, L-lysyl or pyro-L-glutamyl; A is selected from proline, 3, 4-dehydroproline, -methyl proline, thiazolidine-4-carboxylic acid, cycloleucine, pyroglutamic acid, 1-amino-1-cyclopropane carboxylic acid, 1-amino-1-cyclobutane carboxylic acid, 1-amino-1-cyclohexane carboxylic acid and monosubstituted prolines wherein the substituent is halo or hydroxy, and is linked to R through its amino group or imino group and further is linked to S through its carboxyl group; S is a sulfur atom in thioester linkage with A; Z is selected from the following: ##STR69## wherein (i) R 1 and R 2 ', are each hydrogen or halogen, and R 2 and R 3 are each hydrogen, lower alkyl or trifluoromethyl provided that only one of R 2 and R 3 may be trifluoromethyl and further provided that at least one of R 1 , R 1 ', R 2 and R 3 must be halogen or trifluoromethyl (ii) R 23 is hydrogen or lower alkyl and (iii) m is 0 or 1; ##STR70## wherein (i) R 4 and R 5 are each hydrogen, lower alkyl or phenyllower alkylene (ii) N is 1, 2 or 3 (iii) R 6 is hydrogen or hydroxy or when n is 2, R 6 may also be halogen and (iv) m and R 23 are as stated in II. above; ##STR71## wherein (i) R 7 is hydrogen, lower alkanoyl or amino (imino)-methyl; (ii) p is 0 or an integer of from 1 to 4; (iii) R 25 is hydrogen but when m is 1, p is 0, R 4 is hydrogen and R 7 is lower alkanoyl, R 25 may also be lower alkyl; (iv) R 8 is selected from hydrogen, lower alkyl and hydroxy lower alkylene. When R 9 is selected from hydrogen, lower alkyl, phenyl, phenyl-lower alkylene, hydroxy-lower alkylene, hydroxyphenyl-lower alkylene, mercapto-lower alkylene, lower alkylthio-lower alkylene, imidazolyl-lower alkylene, indolyl-lower alkylene, carbamoyl-lower alkylene and carboxy-lower alkylene but R 8 and R 9 may together constitute a (CH 2 )ν bridge wherein ν is 3 or 4, thus forming a 5 or 6-membered ring with the N and C to which R 8 and R 9 are respectively attached and in such instance when ν is 3 one hydrogen of (CH 2 )ν may be replaced by OH or halogen and when ν is 4, one such hydrogen may be replaced by OH; (v) m and R 23 are each as defined in II. above; and (iv) R 4 is as defined in III. above, provided further, however, that m and p may not both be 0. ##STR72## wherein (i) R 10 is hydrogen or lower alkyl; (ii) R 11 is hydrogen, lower alkyl or lower alkanoyl; (iii) X is O or S; (iv) m and R 23 are as stated in II. above, and (v) R 8 , R 9 and p are as stated in IV. above; ##STR73## wherein (i) R 12 is selected from carboxy, lower alkoxycarbonyl, carbamoyl, N-substituted from carboyl and cyano; (ii) m and R 23 are as stated in II. above; and (iii) R 8 , R 9 and p are as stated in IV. above; ##STR74## wherein (i) R 13 is hydrogen, lower alkyl or phenyl-lower alkylene; (ii) R 14 is selected from hydrogen, lower alkyl, phenyl-lower alkylene, hydroxy-lower alkylene, amino lower alkylene, guanidino-lower alkylene, imidazolyl-lower alkylene, indolyl-lower alkylene, mercapto-lower alkylene, lower alkyl-thio-lower alkylene, carbamoyl-lower alkylene and carboxy-lower alkylene; (iii) R 4 and R 5 are each as stated in III, above; and (iv) q is 0, 1 or 2; ##STR75## wherein (i) R 15 and R 16 are each hydrogen, lower alkyl, phenyl or phenyl-lower alkylene; (ii) R is 0, 1 or 2; (iii) S is 1, 2 or 3; (iv) R 17 is hydrogen, hydroxy or lower alkyl and when S is R 17 may also be halogen; (v) R 24 is hydroxy, amino or lower alkoxy; ##STR76## wherein ii) R 18 is hydrogen or lower alkyl; (ii) R 19 and R 20 are each lower alkyl and may together constitute a (CH 2 ).sub.ω bridge wherein ω is 4, to form a ring of 5-carbons with the carbon to which they are each attached; (iii) R 21 is hydrogen or lower alkyl and may constitute with R 9 a (CH 2 )α bridge wherein α is 3, to form a five-membered ring with the N and C to which they are respectively attached; ##STR77## wherein (i) R 22 is hydrogen or lower alkyl; (ii) t is 0 or 1; and (iii) R 26 is selected from ##STR78## wherein μ is 0 or 1 and R 23 is as defined for formula II above, and ##STR79## wherein (i) z is 2 or 3; (ii) R 10 is as stated in V. above; and (iii) R 23 is as stated in II. above.
Claim 3
Dependent Claim
16 words
The compound of claim 1 wherein R is hydrogen, acetyl, benzoyl, cyclopentanecarbonyl, tert-butyloxycarbonyl, cyclopentanecarbonyl-L-lysyl or pyro-L-glutamyl.
Claim 4
Dependent Claim
12 words
The compound of claim 1 wherein Z is defined by formula II.
Claim 5
Dependent Claim
12 words
The compound of claim 1 wherein Z is defined by formula III.
Claim 6
Dependent Claim
12 words
The compound of claim 1 wherein Z is defined by formula IV.
Claim 7
Dependent Claim
12 words
The compound of claim 1 wherein Z is defined by formula V.
Claim 8
Dependent Claim
12 words
The compound of claim 1 wherein Z is defined by formula VI.
Claim 9
Dependent Claim
12 words
The compound of claim 1 wherein Z is defined by formula VII.
Claim 10
Dependent Claim
12 words
The compound of claim 1 wherein Z is defined by formula VIII.
Claim 11
Dependent Claim
12 words
The compound of claim 1 wherein Z is defined by formula IX.
Claim 12
Dependent Claim
12 words
The compound of claim 1 wherein Z is defined by formula X.
Claim 13
Dependent Claim
12 words
The compound of claim 1 wherein Z is defined by formula XI.
Claim 14
Dependent Claim
9 words
The compound of claim 4 wherein n is 2.
Claim 15
Dependent Claim
51 words
The compound of claim 5, 6 or 7 wherein R 8 and R 9 together form a --CH 2 CH 2 CH 2 --bridge which completes a ring of atoms with the nitrogen and carbon to which they are attached, one carbon optionally bearing a hydroxy group or a halogen group.
Claim 16
Dependent Claim
9 words
The compound of claim 9 wherein s is 2
Claim 17
Dependent Claim
38 words
The compound of claim 10 wherein R 19 and R 21 together form a --CH 2 CH 2 CH 2 --bridge which completes a ring of 5 atoms with the nitrogen and carbon to which they are attached.
Claim 18
Dependent Claim
10 words
The compound of claim 11 wherein R 26 is ##STR80##
Claim 19
Dependent Claim
9 words
The compound of claim 12 wherein z is 2.
Claim 20
Dependent Claim
28 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need thereof a therapeutically effective dose of the compound of claim 2.
Claim 21
Dependent Claim
28 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need thereof a therapeutically effective dose of the compound of claim 3.
Claim 22
Dependent Claim
28 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need thereof a therapeutically effective dose of the compound of claim 4.
Claim 23
Dependent Claim
28 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need thereof a therapeutically effective dose of the compound of claim 5.
Claim 24
Dependent Claim
28 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need thereof a therapeutically effective dose of the compound of claim 6.
Claim 25
Dependent Claim
28 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need thereof a therapeutically effective dose of the compound of claim 7.
Claim 26
Dependent Claim
28 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need thereof a therapeutically effective dose of the compound of claim 8.
Claim 27
Dependent Claim
28 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need thereof a therapeutically effective dose of the compound of claim 9.
Claim 28
Dependent Claim
28 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need thereof a therapeutically effective dose of the compound of claim 10.
Claim 29
Dependent Claim
28 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need thereof a therapeutically effective dose of the compound of claim 11.
Claim 30
Dependent Claim
28 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need thereof a therapeutically effective dose of the compound of claim 12.
Claim 31
Dependent Claim
28 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need thereof a therapeutically effective dose of the compound of claim 13.
Claim 32
Dependent Claim
28 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need thereof a therapeutically effective dose of the compound of claim 14.
Claim 33
Dependent Claim
28 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need thereof a therapeutically effective dose of the compound of claim 15.
Claim 34
Dependent Claim
28 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need thereof a therapeutically effective dose of the compound of claim 16.
Claim 35
Dependent Claim
28 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need thereof a therapeutically effective dose of the compound of claim 17.
Claim 36
Dependent Claim
28 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need thereof a therapeutically effective dose of the compound of claim 18.
Claim 37
Dependent Claim
29 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering a therapeutically effective dose of the compound of claim 19.
Claim 38
Dependent Claim
29 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering a therapeutically effective dose of the compound of claim 2.
Claim 39
Dependent Claim
29 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering a therapeutically effective dose of the compound of claim 3.
Claim 40
Dependent Claim
29 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering a therapeutically effective dose o the compound of claim 4.
Claim 41
Dependent Claim
29 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering a therapeutically effective dose of the compound of claim 5.
Claim 42
Dependent Claim
29 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering a therapeutically effective dose of the compound of claim 6.
Claim 43
Dependent Claim
29 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering a therapeutically effective dose of the compound of claim 7.
Claim 44
Dependent Claim
29 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering a therapeutically effective dose of the compound of claim 8.
Claim 45
Dependent Claim
29 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering a therapeutically effective dose of the compound of claim 9.
Claim 46
Dependent Claim
29 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering a therapeutically effective dose of the compound of claim 10.
Claim 47
Dependent Claim
29 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering a therapeutically effective dose of the compound of claim 11.
Claim 48
Dependent Claim
29 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering a therapeutically effective dose of the compound of claim 12.
Claim 49
Dependent Claim
29 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering a therapeutically effective dose of the compound of claim 13.
Claim 50
Dependent Claim
29 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering a therapeutically effective dose of the compound of claim 14.
Claim 51
Dependent Claim
29 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering a therapeutically effective dose of the compound of claim 15.
Claim 52
Dependent Claim
29 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering a therapeutically effective dose of the compound of claim 16.
Claim 53
Dependent Claim
29 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering a therapeutically effective dose of the compound of claim 17.
Claim 54
Dependent Claim
29 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering a therapeutically effective dose of the compound of claim 18.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-05-22 | 1992-11-21 | 1993-05-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-05-22 | 1996-11-21 | 1997-05-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-05-22 | 2000-11-21 | 2001-05-23 | $7700.00 | Window Closed / Lapsed |